ESMO 2025 | Benefits of subcutaneous immunotherapy in reducing cancer care burden

I was honored to present in collaboration with the European Nursing Oncology Society on subcutaneous immunotherapy. As we know there is now a huge pressure across the board on healthcare systems in Europe and also globally and we need now to find innovations to try and reduce that pressure that can be reduced by reducing chair time, reducing the time that patients have to travel to hospital but also reducing the strain on the staff and giving patients that precious time back to their lives. We discussed a couple of trials that have discussed the role of subcutaneous systemic anti-cancer therapies, well-established treatments. So I’ve referenced the PHranceSCa clinical trial, which is a phase two clinical trial that looked at patients’ preference of subcutaneous Fc fusion protein as opposed to the intravenous preparation of trastuzumab-pertuzumab in patients with breast cancer. And I also discussed the IMscin002 trial that looked again at patient’s preference of subcutaneous immunotherapy with atezolizumab in patients with lung cancer as opposed to the IV preparation. In both trials, there was an overwhelming patient preference for the subcutaneous preparation, showing that we have to take patients’ views into account. And what was very special about both trials is they are amongst the occasional trials that actually put patient’s preference as their primary endpoint. And I think we need a lot more trials that look at patient’s preference, patient’s reported outcomes, patient’s quality of life at the forefront of what they’re trying to achieve.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.